BIOMAT Database Logo BIOMAT Database Logo

[Hypopotassemic myopathy caused by topical administration of 9 alpha fluoroprednisolone]. 1987

A Molins, and J Alvarez-Sabín, and J Montalbán, and J Molero, and J Alegre, and A Codina

UI MeSH Term Description Entries
D007008 Hypokalemia Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed) Hypopotassemia,Hypokalemias,Hypopotassemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009135 Muscular Diseases Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE. Muscle Disorders,Myopathies,Myopathic Conditions,Muscle Disorder,Muscular Disease,Myopathic Condition,Myopathy
D005260 Female Females
D005477 Fluprednisolone A synthetic glucocorticoid with anti-inflammatory properties.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006929 Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA. Aldosteronism,Conn Syndrome,Conn's Syndrome,Primary Hyperaldosteronism,Conns Syndrome,Hyperaldosteronism, Primary,Syndrome, Conn,Syndrome, Conn's
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A Molins, and J Alvarez-Sabín, and J Montalbán, and J Molero, and J Alegre, and A Codina
[Hypermineralcorticism caused by topical preparation containing 9-alpha-fluoroprednisolone].
January 1988, Medicina cutanea ibero-latino-americana,
A Molins, and J Alvarez-Sabín, and J Montalbán, and J Molero, and J Alegre, and A Codina
[9-alpha-fluoroprednisolone in the topical therapy of occupational dermatosis caused by alkaline substances].
August 1968, Minerva dermatologica,
A Molins, and J Alvarez-Sabín, and J Montalbán, and J Molero, and J Alegre, and A Codina
[Hypokalemic myopathy and metabolic alkalosis secondary to the topical application of 9-alpha-fluoroprednisolone].
September 1983, Revista clinica espanola,
A Molins, and J Alvarez-Sabín, and J Montalbán, and J Molero, and J Alegre, and A Codina
[Case of pseudohyperaldosteronism caused by 9-alpha-fluoroprednisolone abuse].
July 1985, La Clinica terapeutica,
A Molins, and J Alvarez-Sabín, and J Montalbán, and J Molero, and J Alegre, and A Codina
Hypermineralocorticoidism due to topical application of 9 alpha-fluoroprednisolone.
November 1984, Clinical nephrology,
A Molins, and J Alvarez-Sabín, and J Montalbán, and J Molero, and J Alegre, and A Codina
[Exogenous hypermineralocorticism caused by a nasal spray containing 9-alpha fluoroprednisolone].
January 1984, Minerva cardioangiologica,
A Molins, and J Alvarez-Sabín, and J Montalbán, and J Molero, and J Alegre, and A Codina
Hypertension and hypokalaemia caused by 9 alpha-fluoroprednisolone in a nasal spray.
June 1979, Lancet (London, England),
A Molins, and J Alvarez-Sabín, and J Montalbán, and J Molero, and J Alegre, and A Codina
[9-alpha-fluoroprednisolone in lotion and ointment in topical dermatological therapy].
January 1971, Minerva medica,
A Molins, and J Alvarez-Sabín, and J Montalbán, and J Molero, and J Alegre, and A Codina
[Hypermineralcorticism syndrome secondary to topical application of 9-alpha-fluoroprednisolone (author's transl)].
December 1980, Medicina clinica,
A Molins, and J Alvarez-Sabín, and J Montalbán, and J Molero, and J Alegre, and A Codina
[Anasarca as the form of presentation of exogenous hypermineralocorticism caused by 9 alpha-fluoroprednisolone].
March 1986, Medicina clinica,
Copied contents to your clipboard!